WOBURN, MA / ACCESSWIRE / September 28, 2016 / S.P.O. GLOBAL Inc. (OTC trading symbol “SPOM”), an emerging technology company wishes to update shareholders on a recent event which underpins the increasing valuation of SPOM Global Inc.

Micro Focus International Plc, a multinational UK public company has just publicly announced its intent to merge with HPE (Hewlett Packard Enterprise).

HPE software products includes its application testing product called LoadRunner, which is comparable and in competition to SPO Global Stress Tester.

Owen Dukes, CEO of SPOM comments, “When I look at Micro Focus’ business modal, there is a clear pattern in our market space. Micro Focus has acquired numerous niche software companies in the recent years.

My interpretation of Micro Focus’ business model is to find niche software companies where the barriers to entry are high, with companies that own their IP and have a proven robust and scalable solution with a growing extensive and renewal business.

This can only be seen as a fantastic opportunity for us to ensure that any potential sale our business will receive the best possible valuation while we continue to grow in our market space, as we focus on developing our software to offer our customers a fully feature rich solution.”

Owen Dukes further commented, “With all the recent potential purchase activity recently announced, I wish to inform shareholders that my focus is growing our business and closing large enterprise contracts especially in North America where we are seeing substantial sales opportunities that will only increase the value of our company.”

About S.P.O. Global Inc.

S.P.O. (SOFTWARE PERFORMANCE OPTIMIZATION) GLOBAL INC, is an emerging technology company that is focused on selling its unique performance testing optimization and monitoring software IP for all enterprise applications. The focus of SPO is to build the company into a major player in this exciting billion-dollar market.

SPO Global recently purchased the technology company Reflective Solutions Corp. that sells its unique IP software to major enterprises in North America and Europe.

The principle software products of Reflective Solutions is “Stress Tester” a robust Performance Stress testing solution for large enterprise applications and its new product “Sentinel” that is providing enterprise customers an intelligent monitoring solution 24 / 7 software as a service (SaaS).

For more information on SPO Global visit: www.spoglobal.com

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, expectations regarding the successful expansion of our product base, profitability, market acceptance of our products and new product applications, timing of new product launches, product performance, size of prospective markets, marketing strategies, success of our restructured operations and plans, our ability to generate fees or raise capital to support our business operations and plan, the sufficiency and availability of working capital, changes in economic conditions generally and in more specifically, the introduction of
competing products, changes in our operating strategy or development plans, patent protection for our products and technologies, changes in economic conditions generally and in more specifically, in the markets we operate, changes in technology, legislative or regulatory changes that affect us. We undertake no obligation to revise or update any forward-looking statement for any reason.

SOURCE: SPO GLOBAL Inc.

ReleaseID: 446140

New Extraoral Multi-Modality Dental Imaging System Boasts Exclusive Variable Light-Guided Field-of-View Combined with Lightning Fast Image Reconstruction

VANCOUVER, BC / ACCESSWIRE / September 28, 2016 / LED Medical Diagnostics Inc., through its wholly-owned US and Canadian operating subsidiaries, LED Dental Inc./LED Dental Ltd. (“LED Dental”) is pleased to announce the launch of the RAYSCAN Alpha Plus, a next-generation extraoral imaging system that is the latest innovation from former Samsung Electronics subsidiary RAY Company (“RAY”).

Building upon the award-winning RAYSCAN Alpha platform, the RAYSCAN Alpha Plus continues RAY Company’s dedication to delivering high-quality imaging technologies combined with innovative features that break new ground in the industry.

Clinicians can utilize the RAYSCAN Alpha Plus to capture high-resolution panoramic, cephalometric and cone beam computed tomography images. The panoramic modality allows for a variety of 2D panoramic examinations, including standard pano and segmented pano acquisitions, in addition to an extraoral bitewing feature.

The CBCT modality of the RAYSCAN Alpha Plus boasts several exclusive features that allow practitioners to truly customize examinations to their patients unlike ever before. First, the Alpha Plus utilizes an innovative light-guided field-of-view that simplifies patient positioning to reduce errors and retakes. The desired field-of-view is super-imposed on the patient’s face, allowing dental professionals to see the exact area being scanned in relation to the patient’s actual anatomy, ensuring accurate image acquisition.

Furthermore, the system adds to the innovative light-guided positioning feature by utilizing Free FOV technology, which makes the field-of-view completely customizable from 4×3 cm to 16×10 cm. While many systems on the market force the clinician to choose one of several pre-set field-of-view options, the RAYSCAN Alpha Plus allows practitioners to collimate the field-of-view to any size, truly limiting radiation exposure to the smallest area possible to still acquire the needed anatomy.

While The RAYSCAN Alpha Plus continues to push new boundaries in terms of dose reduction, image quality and clarity remain the system’s top priority. The CBCT modality delivers voxel resolutions as small as 70 μm, making 3D images from the RAYSCAN Alpha Plus among the highest resolution in the industry. And, new proprietary algorithms allow for images to be reconstructed in as little as 4.9 seconds.

Finally, the optional cephalometric module is available in either scanning or one-shot options, with the one-shot module acquiring images in less than one second to further reduce image distortion and lessen radiation dose.

“We could not be more excited to launch the RAYSCAN Alpha Plus in conjunction with our partners at RAY Company,” stated Dr. David Gane, CEO of LED Medical Diagnostics. “Over the last few years, RAY Company has illustrated a commitment to developing technologies that not only deliver exceptional image quality, but also integrate innovative features that make acquiring images more intuitive, delivering an improved user experience while reducing patient dose.”

Kevin Cho, President of RAY America concluded, “The RAYSCAN Alpha Plus is the culmination of years of development and optimization, relying on clinical feedback to build a system that not only produces outstanding images but utilizes next-generation technologies to make oral healthcare a simpler, more patient-friendly process.”

The RAYSCAN Alpha Plus is available now through LED Dental. For more information, please call 844.952.7327 or visit www.leddental.com.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Vancouver, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc. and LED Dental Ltd, provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.

The Company is currently listed on the TSX Venture Exchange (TSX-V) under the symbol “LMD”, the OTCQX under the symbol “LEDIF”, as well as the Frankfurt Stock Exchange under the symbol “LME”. For more information, call 844.952.7327 or visit www.leddental.com/investor-relations.

About RAY Company, Ltd.

Since 2004, RAY has specialized in researching, developing and producing high-quality digital imaging systems for the medical and dental industries. Due to the company’s development of superior imaging technologies, RAY became a subsidiary of worldwide technology leader Samsung Electronics Co., Ltd, in 2010. Under the Samsung brand, RAY Company launched the RAYSCAN Alpha – Expert in 2012 and rapidly penetrated the US market beginning in 2014. With the success of the RAYSCAN Alpha, RAY made the strategic decision to become an independent imaging company in 2015, singularly focused on its future as a leader in the worldwide dental imaging market.Learn more at www.rayamerica.com.

LED Medical Diagnostics

Investor Relations:

Bristol Capital
Glen Akselrod
Phone: 905.326.1888, ext. 10
Email: glen@bristolir.com

Media Contact:

LED Dental
Chris Koch
Phone: 678.293.9413
Email: chris.koch@leddental.com

Corporate Contact:

LED Medical
David Gane, CEO
Phone: 604-434-4614 x227
Email: david.gane@leddental.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company’s future growth strategy, its distribution strategy and product offerings, potential expansion of the Company’s technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation’s actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation’s reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2015. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: LED Medical Diagnostics Inc.

ReleaseID: 446118

DocPath’s Houston Suite is a New Document Output Software Solution for an Optimal Migration Path for Out-of-Support Control-D Applications

SUWANEE, GA / ACCESSWIRE / September 28, 2016 / DocPath launches DocPath Houston Suite, a new document output software solution offering an optimal alternative to legacy, out-of-support Control-D applications.

In response to the manufacturer’s decision of no longer providing maintenance and support services for its Control-D software system, for Unix platforms, DocPath now launches DocPath Houston Suite.

Control-D, developed by BMC Software, is a software product geared towards automated management of reports generated in mainframe and distributed systems. With DocPath document software, Control-D users are now able to smoothly and securely replace their legacy applications with a state-of-the-art Output Management solution. To this end, the power components of the existing DocPath document generation platform have recently been expanded to support the required document distribution requirements – including mainframe-generated reports – on a modern platform using a centralized database-driven repository and a secure Web infrastructure.

The result is DocPath Houston Suite, the new document software solution that has been specifically developed upon request of different DocPath Clients that needed to replace their out-of-support legacy Control-D applications. DocPath Houston Suite seamlessly accommodates the requirements of any organization in need of first-rate and cost-effective replacement software.

About DocPath

DocPath is a leading document software manufacturer that provides its world-wide customers the technology that allows them to implement of sophisticated Customer Communications Management and Document Output Management processes. Created in 1992, DocPath’s solutions are found in companies all over the world. Among its international clients are prestigious banks and first class corporations, which are aided by DocPath solutions by simplifying the complicated and critical task involving the design and distribution of business and customer documents. DocPath maintains a strong commitment to R&D&i, an area that receives a good amount of its revenue, and in which lies the key to the company’s success.

For more information, visit: docpath.com

DISCLAIMER: All names of brands, products, programs, operating systems, processes, etc., which appear in this press release are registered trademarks that belong to their corresponding companies and organizations.

SOURCE: DocPath corp.

ReleaseID: 446117

Widespread Relationships Across the State Increase its Access to Users

MIAMI, FL / ACCESSWIRE / September 28, 2016 / Novus Acquisition and Development, Corp. (OTC Markets: NDEV), the nation’s first healthcare insurance carrier in the medical cannabis field and property and casualty sector, today announced its completed health coverage footprint for medical marijuana (MMJ) in California. Novus’ revolutionary MMJ health plan now covers approximately 110 cities across the state with its relationships with 20 dispensaries. For a complete list of cities and coverage, please visit: http://www.getnovusnow.com/nmg/california.

Frank Labrozzi, Novus’ Chairman and Chief Executive Officer, stated, “This milestone of our Provider Network (dispensaries and/or delivery services) in 100+ cities in California is significant representation of how we built our health insurance infrastructure. The Golden State represents 50% of the cannabis market with close to 1,000,000 registered patients averaging over $300 per month per cannabis transaction. Achieving this significant task puts Novus in a position of no longer turning down any patients for not having a Provider to service their geo-region.”

With Proposition 64 on the ballot this November, all signs are pointing to a 60% approval by California voters. With a GDP of $2.5 trillion per annum, California has the economy that ranks eighth in the world, with marijuana being one of the biggest businesses. An approval would have a tremendously positive impact on Novus, as Proposition 64 imposes an excise tax on retail sales of recreational marijuana at 15% of sales price, and state cultivation taxes on marijuana of $9.25 per ounce of flowers and $2.75 per ounce of leaves resulting in a total retail sales tax of over 20%. However medical marijuana patients will receive an exemption on the taxation leaving Novus patient/members savings of 45% -50% on their monthly med purchases, based on $300 per month, with a minimum annual saving of $1,620 per patient. Drawing consumers ever so closely to medical benefit packages that Novus possess.

Novus is proud to introduce our new providers into our network:

Danko & Dab Co. located in California
Beach Meds located in California
Budee.org located in California
Goldmine located in California
Nice Dreams located in California
Sweet Dreams located in Illinois
We Clone located in California

NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj

About Novus

Novus Acquisition & Development Corp. (NDEV), through its subsidiary Novus Medical Group, Inc. and WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector.

Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.

The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government’s enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.

For more information, check out: http://www.getnovusnow.com
For NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj
Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva

Forward-Looking Statements

This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Corporate:
Chairman and CEO
Frank Labrozzi
frank@ndev.biz
855-228-7355

Investors:
Hayden IR
hart@haydenir.com
917-658-7878

SOURCE: Novus Acquisition & Development Corp.

ReleaseID: 446102

The Small-Batch Distillery Will Use Local Ingredients to Create Flavored Gin, Vodka, and Whisky

LOS ANGELES, CA / ACCESSWIRE / September 28, 2016 / Eric Boesen, an entrepreneur with a passion for creating unique liquors, recently announced the launch of his latest venture, Crescent Moon Spirits LLC. The distillery, which is expected to open in Green Bay, Wisconsin, will produce a variety of flavored gins, vodkas, and whiskeys for the public.

To learn more about Crescent Moon Spirits, please visit goo.gl/3jfq9H.

According to a representative of the establishment, Crescent Moon Spirits LLC is a small craft distillery that produces spirits made from corn, wheat, barely, rice, rye, and malt. Crescent Moon Spirits LLC plans to bring intriguing flavors to the menu, such as apple pie, root beer, and pumpkin pie – and the distillery’s selection of flavored spirits add something extra to classic drinks. Above all, the company supports local businesses and the community by using ingredients from local farms.

“I have come up with and mastered many unique flavors that will be available at Crescent Moon Spirits Small Craft Distillery – that includes vodkas and flavored spirits not like anything else on the market today,” said Boesen.

“Our flavored spirits are steeped with herbs and spices for months to achieve the character and flavor needed before bottling. We are a small craft distillery, but don’t let that fool you.”

At this time, Boesen has taken his project to Kickstarter, where he seeks the necessary funds to bring Crescent Moon Spirits LLC to life. The funds raised will be used to build the establishment, install the still, and begin producing craft spirits. In exchange for the public’s support, Boesen is offering a wide variety of perks, such as branded tumblers, mason jars, and shot glasses.

Individuals interested in learning more about Crescent Moon Spirits can visit the project’s Kickstarter page for additional information.

About Crescent Moon Spirits:

Crescent Moon Spirits, set to open in Green Bay, WI, is a new establishment that mastered the distillation of quality gin, vodka, and whisky. The company is putting an emphasis on keeping it local and supporting the community, especially because ingredients are sourced from local farms. The wheat, rye, barley, corn, and rice used to create these drinks are all local, offering a complimentary touch to the flavors that Eric Boesen has mastered. For more information, please visit https://goo.gl/3jfq9H.

Contact:

Stewart Barber
admin@rocketfactor.com
(949) 555-2861

SOURCE: Crescent Moon Spirits LLC

ReleaseID: 446156

The USB Fingerprint Biometrics Accessories, Tested and Qualified for Windows Hello, are Now Available for Windows 10 Customers

WALL, NJ / ACCESSWIRE / September 28, 2016 / BIO-key International, Inc. (OTCQB: BKYI), an innovative provider of biometric software and hardware solutions for strong and convenient user authentication, announced today that the company’s line of compact USB fingerprint reader accessories have been launched for retail sale on Microsoft’s online store (http://www.microsoftstore.com) and at Microsoft retail stores nationwide, effective September 27, 2016. SideSwipe, SideTouch and EcoID will be available in stores and online at $39.99 each.

Microsoft’s assortment of BIO-key’s biometric accessories in their consumer-targeted stores highlights both the popularity and demand for the password-free Windows Hello feature and the performance and security advantages of BIO-key’s devices, tested and qualified by Microsoft, over the multitude of unqualified fingerprint accessories sold on other marketplaces.

BIO-key’s USB fingerprint accessories and software are amongst the first qualified Windows Hello fingerprint peripherals.

Windows Hello signs you in to Windows devices*, apps and Microsoft Edge websites** 3 times faster than a password that you have to remember and type in***. By using BIO-key’s SideSwipe, SideTouch and EcoID fingerprint accessories, Windows 10 customers can enjoy the convenience and the security of Windows Hello with the convenience of an affordable, easy-to-use accessory.

“I joined BIO-key 13 years ago because of a strong belief that BIO-key’s unique technology could become mainstream and make a difference in people’s lives,” stated Mike DePasquale, Chairman & CEO, BIO-key. “When Microsoft introduced Windows 10 with Windows Hello, its secure biometric sign-in feature, Microsoft validated that biometric technology is going mainstream. Exceeding Microsoft’s demanding standards for security and convenience distinguishes our products from the scores of insecure, untested USB fingerprint scanners in the market, and we are honored to be one of the first Windows Hello accessory chosen by Microsoft to place in its retail stores,” DePasquale added.

“We’re excited to see BIO-key’s line of accessories enter the market as some of the first to use the power of touch to securely and quickly unlock devices*, apps and services** with Windows Hello,” said Aaron Woodman, General Manager, Windows Consumer Marketing at Microsoft.

Click this link to find BIO-key products at Microsoft’s online store.

* Windows Hello requires specialized hardware, including fingerprint reader, illuminated IR sensor or other biometric sensors and capable devices.

** Limited to compatible websites and apps.

***Based on average time comparison between typing a password and time from detecting a face or fingerprint through authentication success

About BIO-key (http://www.bio-key.com)(@BIOkeyIntl)BIO-key is Revolutionizing Authentication as our easy to use biometric solutions enable convenient and secure access to information and financial transactions. We eliminate passwords, PINs tokens and cards and make it easy for enterprises and consumers to secure their devices as well as information in the cloud. Our premium finger scanning devices SideSwipe and EcoID offer market leading quality, performance and price. Now anyone can BIO-key their world! (http://www.bio-key.com)

About Microsoft (NASDAQ: MSFT) (@microsoft) Microsoft is the leading platform and productivity company for the mobile-first, cloud-first world, and its mission is to empower every person and every organization on the planet to achieve more.

BIO-key Safe Harbor Statement

Certain statements contained in this press release may be construed as “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). The words “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbor” provisions of the Act. These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue, our ability to develop new products and evolve existing ones, market acceptance of biometric solutions generally and our specific offerings, our ability to expand into the Asian market, the impact on our business of the recent financial crisis in the global capital markets and negative global economic trends, and our ability to attract and retain key personnel. For a more complete description of these and other risk factors that may affect the future performance of BIO-key International, Inc., see “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made.

Twitter: @BIO_KeyIR
Investor & Media Contacts:
David Collins, William Jones
Catalyst Global
212-984-9800
bkyi@catalyst-ir.com

SOURCE: BIO-key International, Inc.

ReleaseID: 446124